Hypophagia induced by endogenous or liposome-encapsulated 3,4-dihydroxybutanoic acid

Pharmacological approaches for the treatment of obesity

The high incidence of obesity, its multifactorial nature, the complexity and lack of knowledge of the bodyweight control system, and the scarcity of adequate therapeutics have fuelled anti-obesity drug development during a considerable number of years. Irrespective of the efforts invested by researchers and companies, few products have reached a minimum level of effectiveness, and even fewer are available in medical practice. As a consequence of anti-obesity research, our knowledge of the bodyweight control system increased but, despite this, the pharmacological approaches to the treatment of obesity have not resulted yet in effective drugs. This review provides a panoramic of the multiple different approaches developed to obtain workable drugs. These approaches, however, rely in only four main lines of action: control of energy intake, mainly through modification of appetite;control of energy expenditure, essentially through the increase of thermogenesis;control of the availability of substrates to cells and tissues through hormonal and other metabolic factors controlling the fate of the available energy substrates; andcontrol of fat reserves through modulation of lipogenesis and lipolysis in white adipose tissue. A large proportion of current research is centred on neuropeptidic control of appetite, followed by the development of drugs controlling thermogenic mechanisms and analysis of the factors controlling adipocyte growth and fat storage. The adipocyte is also a fundamental source of metabolic signals, signals that can be intercepted, modulated and used to force the brain to adjust the mass of fat with the physiological means available. The large variety of different approaches used in the search for effective anti-obesity drugs show both the deep involvement of researchers on this field and the large amount of resources devoted to this problem by pharmaceutical companies. Future trends in anti-obesity drug research follow closely the approaches outlined; however, the increasing mass of information on the molecular basis of bodyweight control and obesity will in the end prevail in our search for effective and harmless anti-obesity drugs.

Aspectos fisiológicos do balanço energético

Esta revisão apresenta informações a respeito de substâncias fisiológicas que afetam a homeostase energética. Os autores fizeram uma extensa revisão em relação aos mecanismos fisiológicos que modulam o balanço energético quando administrados central ou perifericamente (por exemplo, nutrientes, monoaminas e peptídeos).

[Leptin-induced regulation of fat metabolism and its accumulation]

Recent findings have shown that supplementation of leptin decreases body weight in leptin-deficient ob/ob mice through its suppressive effect on food intake and accelerating effect on energy expenditure, particularly on peripheral fat lipolysis. When endogenously hyperleptinemic obese rats were further induced to be hyperleptinemic exogeously using adenovirus vector, their body fat mass was reduced but not food intake. These findings implicate a direct lipolytic action of leptin on peripheral adipose tissues in obese rats because leptin transport capacity across the blood-brain barrier is almost saturated by the relative hyperleptinemia. Recovery from excessive body fat accumulation after adenovirus-induced hyperleptinemia is much slower than that after caloric restriction because there may be difference between those treatments in decreased lipogenic enzymes activities and/or increased activities of fatty acid oxidative enzymes and thermogenic uncoupling proteins. The fat melting effects of leptin may show its crucial pharmacologic potencies to design therapeutic strategies against morbid obesity. The studies on leptin provide a better understanding for creative approaches to anti-obesity drug that are efficient for reducing body fat mass without harmful side-effects.

Afferent signals regulating food intake

Food intake is a regulated system. Afferent signals provide information to the central nervous system, which is the centre for the control of satiety or food seeking. Such signals can begin even before food is ingested through visual, auditory and olfactory stimuli. One of the recent interesting findings is the demonstration that there are selective fatty acid taste receptors on the tongue of rodents. The suppression of food intake by essential fatty acids infused into the stomach and the suppression of electrical signals in taste buds reflect activation of a K rectifier channel (K 1.5). In animals that become fat eating a high-fat diet the suppression of this current by linoleic acid is less than that in animals that are resistant to obesity induced by dietary fat. Inhibition of fatty acid oxidation with either mercaptoacetate (which blocks acetyl-CoA dehydrogenase) or methylpalmoxirate will increase food intake. When animals have a choice of food, mercaptoacetate stimulates the intake of protein and carbohydrate, but not fat. Afferent gut signals also signal satiety. The first of these gut signals to be identified was cholecystokinin (CCK). When CCK acts on CCK-A receptors in the gastrointestinal tract, food intake is suppressed. These signals are transmitted by the vagus nerve to the nucleus tractus solitarius and thence to higher centres including the lateral parabrachial nucleus, amygdala, and other sites. Rats that lack the CCK-A receptor become obese, but transgenic mice lacking CCK-A receptors do not become obese. CCK inhibits food intake in human subjects. Enterostatin, the pentapeptide produced when pancreatic colipase is cleaved in the gut, has been shown to reduce food intake. This peptide differs in its action from CCK by selectively reducing fat intake. Enterostatin reduces hunger ratings in human subjects. Bombesin and its human analogue, gastrin inhibitory peptide (also gastrin-insulin peptide), reduce food intake in obese and lean subjects. Animals lacking bombesin-3 receptor become obese, suggesting that this peptide may also be important. Circulating glucose concentrations show a dip before the onset of most meals in human subjects and rodents. When the glucose dip is prevented, the next meal is delayed. The dip in glucose is preceded by a rise in insulin, and stimulating insulin release will decrease circulating glucose and lead to food intake. Pyruvate and lactate inhibit food intake differently in animals that become obese compared with lean animals. Leptin released from fat cells is an important peripheral signal from fat stores which modulates food intake. Leptin deficiency or leptin receptor defects produce massive obesity. This peptide signals a variety of central mechanisms by acting on receptors in the arcuate nucleus and hypothalamus. Pancreatic hormones including glucagon, amylin and pancreatic polypeptide reduce food intake. Four pituitary peptides also modify food intake. Vasopressin decreases feeding. In contrast, injections of desacetyl melanocyte-stimulating hormone, growth hormone and prolactin are associated with increased food intake. Finally, there are a group of miscellaneous peptides that modulate feeding. beta-Casomorphin, a heptapeptide produced during the hydrolysis of casein, stimulates food intake in experimental animals. In contrast, the other peptides in this group, including calcitonin, apolipoprotein A-IV, the cyclized form of histidyl-proline, several cytokines and thyrotropin-releasing hormone, all decrease food intake. Many of these peptides act on gastrointestinal or hepatic receptors that relay messages to the brain via the afferent vagus nerve. As a group they provide a number of leads for potential drug development.

Antinociceptive activity of calcitonin and central cholinergic system: behavioural and neurochemical analyses

Behavioural and neurochemical analyses were carried out to investigate the relationship between the antinociceptive activity of porcine calcitonin (pCT) and central cholinergic system in mice and rats. Behavioural studies revealed that the antinociceptive activity of pCT encapsulated in sulphatide-containing liposomes injected intravenously into mice was significantly inhibited by atropine sulphate, but not by atropine methylnitrate, and potentiated by physostigmine, but not by neostigmine. Neurochemical studies using rat brain synaptosomes showed that pCT stimulated synaptosomal sodium-dependent high-affinity choline uptake, which was found to be closely associated with acetylcholine (ACh) synthesis (50-60%). This effect was concentration-dependent. In addition, pCT elicited a biphasic effect on ACh release from synaptosomes with an initial brief period of stimulation and subsequent prolonged inhibition. This stimulation was not affected by atropine sulphate, but markedly reduced by incubation in the presence of diltiazem or in a calcium-free medium, indicating that the modulation of ACh release by the peptide may be mediated by calcium fluxes across the synaptosomal membrane independent of cholinergic receptor activation. However, pCT does not affect the activity of synaptosomal acetylcholinesterase. Therefore, the behavioural study in vivo with the neurochemical analysis in vitro suggests that the central cholinergic system may be involved in the antinociceptive activity of calcitonin.

Biodistribution of calcitonin encapsulated in liposomes in mice with particular reference to the central nervous system

The biodistribution of [125I]porcine calcitonin (pCT) encapsulated in reverse-phase evaporation vesicles (REVs) in mice upon the intravenous administration was examined. It was found that sulfatide significantly improved the stability of REVs in vivo, and altered the relative distribution of [125I]pCT encapsulated in liposomes in mice. These sulfatide-containing REVs were able to target [125I]pCT into the liver and central nervous system (CNS) reasonably well, with the maximal effect of about 40% and 2% of the injected doses occurring at 30 min and 90 min, respectively, after injection. Neither free [125I]pCT, nor sulfatide-free liposome-encapsulated [125I]pCT, nor a mixture of free [125I]pCT and empty sulfatide liposomes was effective. [125I]pCT was widely distributed in the CNS, with predominance in hypothalamus, brainstem, striatum and spinal cord. The results indicate that pCT encapsulated in sulfatide-containing liposomes is able to pass through the blood-brain barrier (BBB), and calcitonin, thus encapsulated, may be applicable to studies on its functions in the CNS.

Structural and stereoisomeric specificity of serum-borne sugar acids related to feeding control by rats

Specificity of chemical structures and stereoisomers among serum-borne short-chain organic acids in rats were assessed for their effects on feeding behavior and humoral factors by infusion into the rat third cerebroventricle. Infusion of glyceric acid (1.0 mumol), 3,4-dihydroxybutanoic acid gamma-lactone (3,4-DB) or 3,4,5-trihydroxypentanoic acid gamma-lactone (2.50 mumol) immediately before the dark phase decreased food intake for, at most, 24 h. These acids did not significantly affect drinking or ambulation. Initial feeding, not necessarily accompanied by periprandial drinking, was induced after infusion of 2,4-dihydroxybutanoic acid gamma-lactone, 2,4,5-trihydroxypentanoic acid gamma-lactone (2,4,5-TP) or exogenous 2,4,5,6-tetrahydroxyhexanoic acid gamma-lactone (2.50 mumol) in the light phase. Of these acids, 3,4-DB most potently suppressed and 2,4,5-TP most potently enhanced feeding. Of these, the 2S,4S-isomer and the 3S-isomer were the most potent of 2,4,5-TP and 3,4-DB, respectively. Only the 2S,4S-isomer of 2,4,5-TP induced hypoglycemia with hyperinsulinemia, whereas opposite effects were produced by the 3S-isomer of 3,4-DB. The results indicate that the positions of the hydroxyl groups on 4-butanolide and the S- and S,S-stereoisomers are important in modulating food intake through the hypothalamus.

Structural characteristics of endogenous sugar acids and relations to feeding modulation

Structural specificity among short-chain organic acids for effects on feeding behavior, blood glucose and insulin was investigated by infusion of 1 exogenous and 6 endogenous derivatives into the rat third cerebral ventricle. Glyceric acid (GEA) (1.0 mumol), 3,4-dihydroxybutanoic acid gamma-lactone (3,4-DB) and 3,4,5-trihydroxypentanoic acid gamma-lactone (3,4,5-TP) (2.50 mumol) decreased food intake for, at most, 24 h. These acids depressed the size of the first meal after infusion, but did not affect latency to the first meal, eating speed, drinking or ambulation. Infusion of 2,4-dihydroxybutanoic acid gamma-lactone (2,4-DB) (1.25 mumol), 2,4,5-trihydroxypentanoic acid gamma-lactone (2,4,5-TP), and an exogenous compound, 2,4,5,6-tetrahydroxyhexanoic acid gamma-lactone (2,4,5,6-TH) (2.50 mumol), induced transient initial feeding which was not necessarily accompanied by periprandial drinking. Ambulation was concomitantly increased. Of these organic acids, 3,4-DB and 2,4,5-TP were most potent in their effects on feeding. Hyperglycemia was induced by 2.50 mumol 3,4-DB leaving insulin unaffected; 2.50 mumol 2,4,5-TP caused hypoglycemia, with a persistent but not significant rise in insulin. The results suggest that slight structural differences of endogenous organic acids, in particular the positions of hydroxyl groups on the lactone ring of 4-butanolide, may be important in feeding modulation by conveying intrinsically reciprocal signals to neurons involved in feeding and satiety.

Clinical ketosis

A diagnosis of primary ketosis is based on clinical signs, clinical pathology, and ruling-out disorders that cause secondary ketosis. Various treatments can be used alone or in combination during the management of clinical ketosis. A treatment should be based on drugs with a mechanism of action that will eliminate the pathogenesis of the clinical signs observed.

Chemical and neuronal control of feeding motivation

The sugar acids, 3,4-dihydroxybutanoic acid gamma-lactone, 2-buten-4-olide and 2,4,5-trihydroxy pentanoic acid gamma-lactone which were found in blood modulate feeding behavior of rats by modifying neuronal activity in the lateral hypothalamic area [LHA] and the ventromedial hypothalamic nucleus [VMH]. The former two act as satiety substances and the latter as a hunger substance. Detection of changes in the concentration of these sugar acids in the blood by glucoreceptor neurons in the VMH and glucose-sensitive neurons in the LHA is important in the regulation of feeding. A phasic increase in fibroblast growth factor [FGF] was found in the cerebrospinal fluid after feeding. Cerebroventricular application of acidic FGF suppresses food intake. Interleukin-1 beta and tumor necrosis factor which have a quite similar amino acid sequence as FGF also suppress feeding. The neuronal mechanism of satiety action of these polypeptides is the same as the sugar acids. The results indicate that these endogenous substances participate in the central regulation of feeding. Hierarchial organization of the endogenous chemical information processing system which is composed of the viscera, medulla, hypothalamus and the cortex is discussed.